Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Abstract

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680 .).

Keywords

MeSH Terms

Affiliated Institutions

• Vall d'Hebron Institute of Oncology
• Hospital Universitario Quirónsalud Madrid ES
• Universidad de Las Palmas de Gran Canaria ES
• Rabin Medical Center IL
• University of California, Los Angeles US
• Ospedale San Luigi Gonzaga IT
• Fondazione IRCCS Istituto Nazionale dei Tumori IT
• Epworth Hospital AU
• Otto Wagner Hospital AT
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Sanford Health US
• Ospedale Policlinico San Martino IT
• Sunnybrook Health Science Centre CA
• University of Turin IT
• Hospital Universitario Insular de Gran Canaria ES
• The Barbara Ann Karmanos Cancer Institute US
• NYU Langone’s Laura and Isaac Perlmutter Cancer Center
• Tel Aviv University IL
• Kansai Medical University JP
• Central University Hospital of Asturias ES
• Health Sciences Centre CA
• Chris O’Brien Lifehouse AU
• Hospital Universitario Fundación Jiménez Díaz ES
• Hebron University PS
• NYU Langone Health US
• Moffitt Cancer Center US
• The University of Sydney AU
• Westmead Hospital AU
• German Center for Lung Research DE

Related Publications